Gasparri, R.; Sabalic, A.; Spaggiari, L. The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers. J. Clin. Med.2023, 12, 7244.
Gasparri, R.; Sabalic, A.; Spaggiari, L. The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers. J. Clin. Med. 2023, 12, 7244.
Gasparri, R.; Sabalic, A.; Spaggiari, L. The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers. J. Clin. Med.2023, 12, 7244.
Gasparri, R.; Sabalic, A.; Spaggiari, L. The Early Diagnosis of Lung Cancer: Critical Gaps in the Discovery of Biomarkers. J. Clin. Med. 2023, 12, 7244.
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide. The main issue is the absence of a screening test available in clinical practice; the identification of non-invasive biomarkers is thus an urgent clinical necessity. Currently, low-dose computed tomography (LD-CT) demonstrates a 20% reduction of lung cancer mortality. However, it is not particularly suitable for clinical practice because of the costs, radiation, and the false positive rate. Several studies have therefore focused on research into biomarkers in body fluids. Despite the power of certain molecules to distinguish lung cancer patients from healthy subjects, no biomarker has yet been shown to significantly and reliably influence clinical decisions or to be translated from the laboratory to clinical practice.
We performed an overview of the peer-reviewed biomedical literature published in the last 10 years on the research regarding biomarkers for the early diagnosis of lung cancer via a comprehensive analysis of the reviews published this past year. Our main aim was to bring to light the limitations and strengths of the research already conducted. Furthermore, future prospectives have been explored, bearing in mind the management of clinical trials and their integration into clinical practice.
Keywords
Early diagnosis; lung cancer; biomarkers; body fluids; research management
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.